Cytomegalovirus infection of the ileoanal pouch: Clinical characteristics and outcomes

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2394-2399

  McCurdy, Jeffrey D ^a   Loftus Jr , Edward V ^a   Tremaine, William J ^a   Smyrk, Thomas C ^a   Bruining, David H ^a   Pardi, Darrell S ^a   Raffals, Laura E ^a   Kisiel, John B ^a   Coelho Prabhu, Nayantara ^a   Kane, Sunanda V ^a   Faubion, William A ^a   Papadakis, Konstantinos A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytomegalovirus; Ileal pouch anal anastomosis; Pouchitis

Indexed keywords

GANCICLOVIR;

ABDOMINAL PAIN; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; ENTERITIS; FEMALE; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE ULCER; LIVER TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROCTOCOLECTOMY; SCHOOL CHILD;

ADULT; ANASTOMOSIS, SURGICAL; ANTIVIRAL AGENTS; CHILD; COLONIC POUCHES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; PROGNOSIS; RECURRENCE; YOUNG ADULT;

EID: 84888255636     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182a52553     Document Type: Article

References (43)

1. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.
2. Pardi DS, DHaens G, Shen B, et al. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis. 2009;15:1424-1431.
3. Stocchi L, Pemberton JH. Pouch and pouchitis. Gastroenterol Clin North Am. 2001;30:223-241.
4. Ferrante M, Declerck S, De Hertogh G, et al. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2008;14:20-28.
5. Shen B. Acute and chronic pouchitis-pathogenesis, diagnosis and treatment. Nat Rev Gastroenterol Hepatol. 2012;9:323-333.
6. Hueting WE, Buskens E, van der Tweel I, et al. Results and complications after ileal pouch anal anastomosis: A meta-analysis of 43 observational studies comprising 9,317 patients. Dig Surg. 2005;22:69-79.
7. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: Analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257:679-685.
8. Coffey JC, Rowan F, Burke J, et al. Pathogenesis of and unifying hypothesis for idiopathic pouchitis. Am J Gastroenterol. 2009;104:1013-1023.
9. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
10. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301-305.
11. Navaneethan U, Shen B. Secondary pouchitis: those with identifiable etiopathogenetic or triggering factors. Am J Gastroenterol. 2010;105: 51-64.
12. Moonka DD, Furth EEE, MacDermott RPR, et al. Pouchitis associated with primary cytomegalovirus infection. Am J Gastroenterol. 1998;93: 264-266.
13. Tribonias G, Karmiris K, Giannikaki E, et al. Detection of CMV in pouch mucosa in a patient with acute pouchitis: the real enemy or an innocent bystander J Crohns Colitis. 2012;6:728-729.
14. He X, Bennett AE, Lian L, et al. Recurrent cytomegalovirus infection in ileal pouch-anal anastomosis for ulcerative colitis. Inflamm Bowel Dis. 2009;16:903-904.
15. Muñoz-Juarez M, Pemberton JH, Sandborn WJ, et al. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum. 1999;42:117-120.
16. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76-98. Table of Contents.
17. Staras SAS, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis. 2006; 43:1143-1151.
18. Lawlor G, Moss AC. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander Inflamm Bowel Dis. 2010;16:1620-1627.
19. Roblin X, Pillet S, Berthelot P, et al. Prevalence of cytomegalovirus infection in steroid-refractory Crohns disease. Inflamm Bowel Dis. 2012;18:E1396-E1397.
20. Kim YS, Kim YH, Kim JS, et al. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: A prospective multicenter study. J Clin Gastroenterol. 2012;46:51-56.
21. Papadakis KA, Tung JK, Binder SW, et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol. 2001;96:2137-2142.
22. Al-Zafiri R, Gologan A, Galiatsatos P, et al. Cytomegalovirus complicating inflammatory bowel disease: A 10-year experience in a community-based, university-affiliated hospital. Gastroenterol Hepatol (N Y). 2012;8:230-239.
23. Kishore J, Ghoshal U, Ghoshal UC, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol. 2004;53:1155-1160.
24. Wada Y, Matsui T, Matake H, et al. Intractable ulcerative colitis caused by cytomegalovirus infection: A prospective study on prevalence, diagnosis, and treatment. Dis Colon Rectum. 2003;46:S59-S65.
25. Galiatsatos P, Shrier I, Lamoureux E, et al. Meta-analysis of outcome of cytomegalovirus colitis in immunocompetent hosts. Dig Dis Sci. 2005;50: 609-616.
26. Domenech E, Vega R, Ojanguren I, et al. Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis. 2008;14:1373-1379.
27. Pillet S, Pozzetto B, Jarlot C, et al. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis. 2012;44: 541-548.
28. Casadesus DD, Tani TT, Wakai TT, et al. Possible role of human cytomegalovirus in pouchitis after proctocolectomy with ileal pouch-anal anastomosis in patients with ulcerative colitis. World J Gastroenterol. 2007;13:1085-1089.
29. Roblin X, Pillet S, Oussalah A, et al. Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis. Am J Gastroenterol. 2011;106:2001-2008.
30. Kuwabara A, Okamoto H, Suda T, et al. Clinicopathologic characteristics of clinically relevant cytomegalovirus infection in inflammatory bowel disease. J Gastroenterol. 2007;42:823-829.
31. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994;107:1856-1860.
32. Suzuki H, Kato J, Kuriyama M, et al. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol. 2010;16:1245-1251.
33. Wolf JM, Achkar JP, Lashner BA, et al. Afferent limb ulcers predict Crohns disease in patients with ileal pouch-anal anastomosis. Gastroenterology. 2004;126:1686-1691.
34. Katsolis JG, Bosch W, Heckman MG, et al. Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients. Transpl Infect Dis. 2013;15:171-180.
35. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med. 2010;267:483-501.
36. Leal RF, Coy CSR, Ayrizono MLS, et al. Differential expression of proinflammatory cytokines and a pro-apoptotic protein in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. Tech Coloproctol. 2008;12:33-38.
37. Leal RF, Ayrizono MLS, Milanski M, et al. Activation of signal transducer and activator of transcription-1 (STAT-1) and differential expression of interferon-gamma and anti-inflammatory proteins in pelvic ileal pouches for ulcerative colitis and familial adenomatous polyposis. Clin Exp Immunol. 2010;160:380-385.
38. You DM, Johnson MD. Cytomegalovirus infection and the gastrointestinal tract. Curr Gastroenterol Rep. 2012;14:334-342.
39. Razonable RR. Strategies for managing cytomegalovirus in transplant recipients. Expert Opin Pharmacother. 2010;11:1983-1997.
40. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother. 2000;44:2811-2815.
41. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7:2106-2113.
42. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol. 2006;101:2857-2865.
43. Criscuoli V, Rizzuto MR, Cottone M. Cytomegalovirus and inflammatory bowel disease: Is there a link World J Gastroenterol. 2006;12:4813-4818.